Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma
Basic Information
Funding Cycle :
2022-2023, 2023-2024
Name :
Eric Smith
Type of Award :
Translational Research Award
Home Institution :
Dana-Farber Cancer Institute
Description
This project aims to develop an optimized dual-targeted tandem VH-only fully-human CAR for the treatment of multiple myeloma, aiming to achieve durable remissions. Specific aims include analyzing factors associated with CAR T cell manufacturing success, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers for treatment response and resistance, and comparing T cell compartments from leukapheresis and autologous stem cell products. The project leverages previous advancements in CAR T cell therapy to enhance efficacy while minimizing toxicity, ultimately aiming to advance the therapy towards clinical translation.
